Since 1869, when Swiss chemist Friedrich Miescher first identified DNA, and the subsequent discovery of the double helix1 by James Watson and Francis Crick, scientists have been working on advancing our understanding of the role genes play in determining how living organisms grow and develop. And as our understanding of genetics and genomics has continued to grow, the biotechnology industry is entering a new era, with the potential to revolutionize the way diseases are treated.
But how does this knowledge translate into tangible treatments that have the potential to benefit patients, especially in diseases that have seen slow progress in the form of meaningful treatments?
Biogen is collaborating with Sangamo Therapeutics to develop and commercialize gene-regulation therapies, starting with genes linked to Alzheimer’s disease, Parkinson’s disease, and an undisclosed neuromuscular disease, with the right to nominate up to nine more targets over a five-year period. Bringing together Sangamo’s genomic expertise and proprietary technology with Biogen’s proven track-record in developing and delivering treatments for neurological diseases, this collaboration is driven by a shared passion for science and a commitment to making a difference for patients.